Scarica l'app Stockscreener
4.85
2.32%
-0.115
Dopo l'orario di chiusura:
4.83
-0.02
-0.41%
Precedente Chiudi:
$4.965
Aprire:
$4.98
Volume 24 ore:
67,383
Relative Volume:
0.80
Capitalizzazione di mercato:
$46.97M
Reddito:
$1.15M
Utile/perdita netta:
$-46.90M
Rapporto P/E:
-0.9665
EPS:
-5.0182
Flusso di cassa netto:
$-42.37M
1 W Prestazione:
-5.09%
1M Prestazione:
-31.50%
6M Prestazione:
-68.59%
1 anno Prestazione:
-66.62%
Intervallo 1D:
$4.85
$5.29
Intervallo di 1 settimana:
$4.85
$5.44
Portata 52W:
$4.85
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
4.85 | 48.08M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics Inc (MCRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Seres Therapeutics Inc Revenue Breakdown – BX:MCRB - TradingView
Seres Therapeutics Inc (MCRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MCRB|Seres Therapeutics Inc|Price:4.980|Chg%:-0.250 - TradingKey
Seres Therapeutics Inc (MCRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary - Quartr
Seres Therapeutics (MCRB) Plunges 9%: Key Support and Resistance Levels in FocusIsland Reversal - dars.gov.et
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14 - Stock Titan
Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere - Stock Titan
[Form 4] Seres Therapeutics, Inc. Insider Trading Activity - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Claire Fraser - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Robert L. Rosiello - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Stephen Berenson - Stock Titan
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study - Yahoo Finance
Seres Therapeutics, Inc. Amends and Restates 2025 Incentive Award Plan in SEC 8-K Filing - Minichart
Seres Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Seres Therapeutics (NASDAQ: MCRB) investors back 900,000-share 2025 incentive plan increase - Stock Titan
Seres Therapeutics (MCRB) Q4 2025 earnings summary - Quartr
Why Is Seres Therapeutics Stock Falling Today?Seres Therapeutics (NASDAQ:MCRB) - Benzinga
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related AndropilatisSlideshow (NASDAQ:MCRB) 2026-07-08 - Seeking Alpha
Seres Therapeutics reports positive early SER-155 data - grafa.com
Seres’ SER-155 takes on immune checkpoint inhibitor-related enterocolitis - BioWorld News
MCRB: All proposals, including director elections and incentive plan amendment, were approved - TradingView
Seres reports trial results for experimental colitis treatment - Investing.com
Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell - Moomoo
Seres Therapeutics reports positive SER-155 trial results - TipRanks
Seres Therapeutics (NASDAQ: MCRB) highlights promising SER-155 data and limited cash runway - Stock Titan
Seres Therapeutics unveils promising IST results for SER-155 in irEC patients - Traders Union
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment - The Manila Times
Seres Therapeutics outlines its microbiome drug strategy as MCRB works to regain traction - ad-hoc-news.de
Price to book forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
Seres Therapeutics (MCRB) Holds Near Support Amid Modest DeclineTrend Following Picks - dars.gov.et
MCRBSeres Therapeutics Inc Dividends - Finviz
MCRB News | SERES THERAPEUTICS INC (NASDAQ:MCRB) - ChartMill
Form 4 Seres Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Seres Therapeutics (NASDAQ: MCRB) director receives 7,508-share stock option grant - Stock Titan
Seres Therapeutics (NASDAQ: MCRB) director awarded 7,508 stock options at $7.94 - Stock Titan
Seres Therapeutics (MCRB) director awarded 7,508 stock options vesting by 2027 - Stock Titan
Clostridium Difficile Infections Market Forecast Signals Robust Industry Growth Through 2034 – DelveInsight | Seres Therapeutics, Nestlé Health Science, Adiso Therapeutics, Deinove, Acurx Pharma - Barchart.com
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
Price to sales forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
Price to earnings forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
Seres Therapeutics to Host Webcast on July 8, 2026, to - GlobeNewswire
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Insulet analyst begins coverage on a bullish note; here are top 5 initiations for Tuesday - MSN
H.C. Wainwright Initiates Seres Therapeutics(MCRB.US) With Buy Rating, Announces Target Price $12 - Moomoo
MCRB Initiates Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):